A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Official title

A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID

NCT01053988

Recruitment status

Completed

Study type

Interventional

Phase

Phase 3

Lead sponsor

GlaxoSmithKline

Industry

Enrollment

1,031 participants

Conditions and interventions

Eligibility (public fields only)

Age range

40 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Oct 5, 2009 (Type not available)

Primary completion

Feb 1, 2011 (Actual)

Completion

Apr 14, 2011 (Actual)

Last update posted

Jul 12, 2018

2009 – 2011

United States locations

U.S. sites

47

U.S. states

20

U.S. cities

45

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.